Intravenous administration of acetaminophen (APAP) may be less effective than oral administration of APAP for reducing opioid use after total hip or knee arthroplasty.
Investigators conducted a meta-analysis to identify predictors of poor postoperative pain control with a goal of developing personalized care pathways to improve outcomes.
Preoperative long-acting opioid use was found to be associated with longer lengths of hospital stay and increased all-cause and pain-related readmission in patients undergoing inpatient and ambulatory surgeries, respectively.
Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery.
From 2013 to 2017, the rate of receiving a take-home opioid prescription remained stable after pediatric outpatient surgery as did the dose prescribed, but the maximum take-home dose declined.
The Food and Drug Administration (FDA) has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery.
Implementation of a novel enhanced recovery after surgery (ERAS) protocol can reduce patients’ postoperative opioid requirements after elective spinal or peripheral nerve surgery.
Data from two Phase 3 studies showed a greater proportion of patients treated with Inveltys having complete resolution of ocular inflammation and pain compared with placebo.
Women undergoing cancer-related breast surgery who display high temporal summation of pain and negative affect before surgery were found to be more likely to experience significant postsurgical pain and continued opioid use.
Implementation of an ultrarestrictive protocol for opioid prescriptions was found to be associated with reductions in the amount of opioids prescribed after abdominal and gynecologic surgery.